Bacterial pneumonia cost-effectiveness of therapy
|
Bacterial pneumonia Microchapters |
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Bacterial pneumonia cost-effectiveness of therapy On the Web |
|
American Roentgen Ray Society Images of Bacterial pneumonia cost-effectiveness of therapy |
|
Bacterial pneumonia cost-effectiveness of therapy in the news |
|
Risk calculators and risk factors for Bacterial pneumonia cost-effectiveness of therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Arooj Naz, M.B.B.S
Overview
The use of antibiotics and corticosteroids had proven to be a cost-effective strategy in treating community-acquired pneumonia. Together, they resulted in savings of $142,795 per death averted. In severe cases of community-acquired pneumonia, the combination of antibiotics and corticosteroids yielded savings of $70,587 and had an 82.6% chance of being cost-effective.[1] The cost effectiveness of ceftolozane/tazobactam versus meropenem was also analyzed and resulted in significant savings in early treatment.[2].
References
- ↑ Pliakos EE, Andreatos N, Tansarli GS, Ziakas PD, Mylonakis E (2019). "The Cost-Effectiveness of Corticosteroids for the Treatment of Community-Acquired Pneumonia". Chest. 155 (4): 787–794. doi:10.1016/j.chest.2018.11.001. PMID 30448195.
- ↑ Naik J, Puzniak L, Critchlow S, Elsea D, Dillon RJ, Yang J (2021). "Cost Effectiveness of Ceftolozane/Tazobactam Compared with Meropenem for the Treatment of Patients with Ventilated Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia". Infect Dis Ther. 10 (2): 939–954. doi:10.1007/s40121-021-00436-4. PMC 8034281 Check
|pmc=value (help). PMID 33837518 Check|pmid=value (help).